Nov 21, 2019
Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH
Company Overview
Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™).
Programs
ALT-801
ALT-801 is a novel peptide-based dual GLP-1/glucagon receptor agonist designed to treat the underlying metabolic dysfunction that leads to non-alcoholic steatohepatitis (NASH). NASH is the most severe form of non-alcoholic fatty liver disease (NAFLD) characterized by abnormal accumulation of fat in the liver, toxic lipid metabolites, inflammation and liver cell damage leading to fibrosis. ALT-801 acts earlier in liver disease progression than other NASH candidates in development and has the potential to reverse metabolic and liver dysfunction as demonstrated in relevant animal models.
HepTcell™
HepTcell is an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (“HBV”). It is designed to drive CD4+ and CD8+ T-cell responses against all HBV genotypes in patients of all ethnic backgrounds. Stimulating T cell responses in chronically infected HBV patients has been challenging because chronic infection with HBV strongly diminishes T cell immunity directed against the virus.
ALT-702
ALT-702 is a targeted tumor immunostimulant product candidate that comprises of a highly potent and selective dual TLR7/8 agonist conjugate designed to overcome the safety limitations of other tumor immune stimulants. ALT-702 is being developed to act locally to reverse local immunosuppression within the tumor microenvironment and stimulate antitumor immune responses. ALT-702 also has the potential to synergize with other local and systemic treatment modalities. Altimmune is currently progressing with the preclinical development plan.
NasoVAX™
NasoVAX™, our most advanced product candidate is an intranasally administered recombinant influenza vaccine, uses an adenovector to achieve expression of the influenza antigen in the target cell, thereby potentially stimulating a broader and more rapid immune response than traditional influenza vaccines.
NasoShield™
NasoShield™, a first-in-class anthrax vaccine designed to provide rapid, stable protection after intranasal administration is being developed with the support of the U.S. Biomedical Advanced Research and Development Authority. NasoShield is based on our RespirVec technology to provide protection following intranasal administration as opposed to multiple injections.